StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) stock

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 14/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $281.77MP/E 5.0Yield –

Elite Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Elite Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 43.7%. For fiscal 2026 it was 50.4%, against 47.7% the year before. The highest annual figure on record is 64.1% in fiscal 2016.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2026Mar 31, 202650.4%+2.7
FY2025Mar 31, 202547.7%+1.2
FY2024Mar 31, 202446.5%−2.0
FY2023Mar 31, 202348.6%+2.7
FY2022Mar 31, 202245.9%−0.9
FY2021Mar 31, 202146.8%+2.4
FY2020Mar 31, 202044.3%+6.5
FY2019Mar 31, 201937.9%−15.0
FY2018Mar 31, 201852.9%+14.1
FY2017Mar 31, 201738.8%−25.3
FY2016Mar 31, 201664.1%+24.2
FY2015Mar 31, 201539.9%+10.2
FY2014Mar 31, 201429.7%−2.3
FY2013Mar 31, 201332.0%−26.2
FY2012Mar 31, 201258.2%+20.9
FY2011Mar 31, 201137.3%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q2 FY2027CQ3 2026Sep 30, 202639.9%+1.1
Q1 FY2027CQ2 2026Jun 30, 202641.7%−26.0
Q4 FY2026CQ1 2026Mar 31, 202651.0%−3.1
Q3 FY2026CQ4 2025Dec 31, 202541.0%−1.6
Q2 FY2026CQ3 2025Sep 30, 202538.7%−4.7
Q1 FY2026CQ2 2025Jun 30, 202567.7%+22.6
Q4 FY2025CQ1 2025Mar 31, 202554.1%+8.8
Q3 FY2025CQ4 2024Dec 31, 202442.6%−2.7
Q2 FY2025CQ3 2024Sep 30, 202443.4%−2.1
Q1 FY2025CQ2 2024Jun 30, 202445.1%−7.8
Q4 FY2024CQ1 2024Mar 31, 202445.2%+5.4
Q3 FY2024CQ4 2023Dec 31, 202345.3%−7.9
Q2 FY2024CQ3 2023Sep 30, 202345.5%+1.0
Q1 FY2024CQ2 2023Jun 30, 202352.9%+0.8
Q4 FY2023CQ1 2023Mar 31, 202339.8%−4.7
Q3 FY2023CQ4 2022Dec 31, 202253.2%+8.4
Q2 FY2023CQ3 2022Sep 30, 202244.5%+0.5
Q1 FY2023CQ2 2022Jun 30, 202252.1%+1.7
Q4 FY2022CQ1 2022Mar 31, 202244.5%+2.1
Q3 FY2022CQ4 2021Dec 31, 202144.8%−11.5
Q2 FY2022CQ3 2021Sep 30, 202144.0%−4.9
Q1 FY2022CQ2 2021Jun 30, 202150.4%+10.9
Q4 FY2021CQ1 2021Mar 31, 202142.5%−7.3
Q3 FY2021CQ4 2020Dec 31, 202056.3%−0.9
Q2 FY2021CQ3 2020Sep 30, 202048.9%+20.3
Q1 FY2021CQ2 2020Jun 30, 202039.5%+0.8
Q4 FY2020CQ1 2020Mar 31, 202049.7%+10.1
Q3 FY2020CQ4 2019Dec 31, 201957.2%+22.9
Q2 FY2020CQ3 2019Sep 30, 201928.7%−31.5
Q1 FY2020CQ2 2019Jun 30, 201938.7%+11.4
Q4 FY2019CQ1 2019Mar 31, 201939.7%−31.5
Q3 FY2019CQ4 2018Dec 31, 201834.3%−9.7
Q2 FY2019CQ3 2018Sep 30, 201860.2%−1.9
Q1 FY2019CQ2 2018Jun 30, 201827.3%−13.1
Q4 FY2018CQ1 2018Mar 31, 201871.1%−16.1
Q3 FY2018CQ4 2017Dec 31, 201744.0%+18.1
Q2 FY2018CQ3 2017Sep 30, 201762.1%–
Q1 FY2018CQ2 2017Jun 30, 201740.4%–
Q4 FY2017CQ1 2017Mar 31, 201787.3%–
Q3 FY2017CQ4 2016Dec 31, 201625.9%–

More Elite Pharmaceuticals figures

See a number that looks wrong?